Skip to main content

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

 


Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails.

There are three types of epidermolysis bullosa which includes:

·         Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe

·         Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe

·         Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe

The type reflects where on the body the blistering takes place and which layer of skin is affected.

Global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and is expected to exhibit a CAGR of 11.2% over the forecast period (2022-2030)

Global Epidermolysis Bullosa Market Restraint

The high treatment cost of epidermolysis bullosa is expected to hinder the market growth over the forecast period.

For instance, according to the data published in the National Center for Biotechnology Information on September 8, 2020, the average monthly bandage cost epidermolysis bullosa range from US$ 262 to > US$ 2,000.

 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more

Fc Protein and Glycoengineered Antibodies Market Is Booming Worldwide 2023-2028

  Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.  Increasing preva...
Post a Comment
Read more